This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Chong Kun Dang Pharmaceutical Corp.
Drug Names(s): CKD391, CKD 391, atorvastatin/ezetimibe
CKD-391 is an orally administered fixed dose combination of atorvastatin and ezetimibe.
Atorvastin calcium inhibits HMG-CoA reductase, an enzyme required for the synthesis of cholesterol.
Ezetimibe lowers cholesterol by localizing at the brush border of the small intestine to inhibit cholesterol absorption. This mechanism of action makes ezetimibe complementary to statins, which work by inhibiting cholesterol synthesis in the liver.
Pink Sheet Chart: Weekly Trademark Review
Additional information available to subscribers only: